Cyclacel Pharmaceuticals Reports Q2 2025 Financial Results

Cyclacel Pharmaceuticals ( (CYCC) ) has released its Q2 earnings. Here is a breakdown of the information Cyclacel Pharmaceuticals presented to its investors.

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer medicines, particularly in the fields of cell cycle, epigenetics, and mitosis biology. The company is working on a diversified pipeline of novel drug candidates targeting oncology and hematology indications.

In its recent earnings report for the second quarter of 2025, Cyclacel Pharmaceuticals highlighted several strategic and financial developments. The company declared quarterly cash dividends on its preferred stock and announced a share exchange agreement with FITTERS Diversified Berhad. Additionally, Cyclacel completed a securities purchase agreement, raising $3 million through the issuance of convertible preferred stock.

Financially, Cyclacel reported cash and cash equivalents of $4.3 million as of June 30, 2025, an increase from $3.2 million at the end of 2024. The company’s net loss for the quarter was $1.3 million, a significant reduction from the $3.3 million loss in the same period of the previous year. This improvement was attributed to decreased research and development expenses following the liquidation of its UK subsidiary and reduced general and administrative costs.

Cyclacel’s strategic moves, including the reverse stock split and share exchange agreement, are aimed at strengthening its financial position and expanding its business operations. The company’s management remains focused on advancing its drug development programs and maintaining compliance with Nasdaq’s listing requirements.

Looking ahead, Cyclacel Pharmaceuticals is poised to continue its efforts in developing its pipeline of cancer therapies while managing its financial resources to support ongoing operations into the fourth quarter of 2025.